Novartis Q211 Revenues Benefit From Alcon Acquisition And Currency Effects

BMI View: Novartis will outperform rival pharmaceutical companies over the medium term and therefore continue to be an attractive prospect for investment. The Basel-based firm increasingly appreciates the opportunities presented by emerging markets, which BMI believes will drive industry growth. Accessing emerging markets is also a vital strategy in maintaining revenue growth, particularly as the US and Europe currently account for more than 50% of the company's revenue. However, we note that the company's strength will be tested as a number of its drugs are set to face competition from generic drugs. Furthermore, we note the company will have to

To read the full article, please choose one of the following options: